Abstract: Medical devices, such as endoprostheses, and methods of making the devices are disclosed. The endoprostheses comprise a tubular member capable of maintaining patency of a bodily vessel. The tubular member includes a duplex stainless steel (e.g., 2205 stainless steel), which may be magnetized.

Abstract: Medical devices with surfaces on which viable biologic cells are magnetically attracted and retained are disclosed along with methods of magnetic coating. The medical devices can be located in a carrier liquid containing high concentrations of magnetic cells before or after implantation. The carrier liquid with magnetic cells may be contact with the medical device in vitro or in vivo. In either case, the carrier liquid may have a concentration of magnetic cells that is high enough to facilitate coating of the medical device within an acceptable period of time, e.g., several hours or less. Magnetization of medical devices before, during, and/or after implantation and apparatus for performing the same are disclosed. Degaussing of magnetic medical devices is also disclosed.

Abstract: Materials and methods for making conformable stents. The stents can be generated by, for example, injecting a fluid into a scaffold on the outer surface of an angioplasty balloon inflated at the site of a stenosis, and allowing the fluid to harden or set, thus generating a stent that can remain in the vessel at the site of stenosis.

Abstract: A method of detecting healing adjacent to an implanted medical device can first include pre-treating a surface of the medical device prior to implantation, thereby defining a pre-treated surface of the medical device. Then, subsequent to implantation, a portion of the pre-treated surface that is not covered by endothelial tissue is detected by a detection device.

Abstract: This document relates to molecularly imprinted polymers for use in mammals. For example, methods and materials for capturing a molecule in the body of a mammal using a molecularly imprinted polymer are provided. In some cases methods for delivering a molecule using a molecularly imprinted polymer into the body of a mammal are provided. The methods provided can be used to target any molecule in the body of a mammal.

Abstract: Systems and methods that provide magnetically-enhanced delivery of therapeutic agents to selected tissue are disclosed. The systems and methods involve the use of carrier devices and release devices and two different magnetic fields to move magnetic particles into selected tissue. Movement of the magnetic particles (and any associated therapeutic agent) into the tissue may be assisted by both magnetic attractive forces as well as magnetic repulsive forces.

Abstract: Medical devices with surfaces on which viable biologic cells are magnetically attracted and retained are disclosed along with methods of magnetic coating. The medical devices can be located in a carrier liquid containing high concentrations of magnetic cells before or after implantation. The carrier liquid with magnetic cells may be contact with the medical device in vitro or in vivo. In either case, the carrier liquid may have a concentration of magnetic cells that is high enough to facilitate coating of the medical device within an acceptable period of time, e.g., several hours or less. Magnetization of medical devices before, during, and/or after implantation and apparatus for performing the same are disclosed. Degaussing of magnetic medical devices is also disclosed.

Abstract: Materials and methods for making conformable stents. The stents can be generated by, for example, injecting a fluid into a scaffold on the outer surface of an angioplasty balloon inflated at the site of a stenosis, and allowing the fluid to harden or set, thus generating a stent that can remain in the vessel at the site of stenosis.

Abstract: Materials and methods for placement of catheters, stents, and other therapeutic or diagnostic devices in blood vessels.

Abstract: This document provides methods and materials that can be used to reduce or prevent contrast agent-induced toxicity. For example, devices for capturing contrast agents from blood are provided.

Abstract: Devices and methods for crossing total chronic occlusions in body lumens (e.g., blood vessels, etc.). The devices and methods may involve guidewire assisted delivery of a device designed to both traverse a chronic total occlusion (CTO) and create a passageway through the CTO for a treatment device (e.g., an angioplasty balloon, stent, etc.). Some devices of the present invention may include an expandable sleeve constructed of material that expands in response to temperature changes. In other devices, an expandable sleeve may be provided in which two or more interlocking cylindrical sections can be arranged such that the cylindrical sections have a first, smaller diameter at which the expandable sleeve can be inserted through a CTO.

Abstract: Medical devices with surfaces on which viable biologic cells are magnetically attracted and retained are disclosed along with methods of magnetic coating. The medical devices can be located in a carrier liquid containing high concentrations of magnetic cells before or after implantation. The carrier liquid with magnetic cells may be contact with the medical device in vitro or in vivo. In either case, the carrier liquid may have a concentration of magnetic cells that is high enough to facilitate coating of the medical device within an acceptable period of time, e.g., several hours or less. Magnetization of medical devices before, during, and/or after implantation and apparatus for performing the same are disclosed. Degaussing of magnetic medical devices is also disclosed.

Abstract: Apparatus, kits and methods for flaring an end of a stent that can then be placed within the ostium of a vessel are disclosed. Areas in which ostial stents with flared ends could be used may include, e.g., the left main artery, renal arteries, sub-clavian artery, right coronary artery, circumflex artery, et al.

Abstract: Nucleic acid probes and primers are described for detecting fungi that cause disease in humans and animals, as well as spoilage of food and beverages. These probes can detect rRNA, rDNA or polymerase chain reaction products from a majority of fungi in clinical, environmental or food samples. Nucleic acid hybridization assay probes specific for Acremonium sp., Aspergillus clavatus, Aspergillus flavus, Aspergillus fumigatus, Aspergillus glaucus, Aspergillus nidulans, Aspergillus niger, Aspergillus ochraceus, Aspergillus terreus, Aspergillus unguis, Aspergillus ustus, Beauveria sp., Bipolaris sp., Blastoschizomyces sp., Blastomyces dermatitidis, Candida albicans, Candida glabrata, Candida guilliermondii, Candida kefyr, Candida krusei, Candida lusitaniae, Candida parapsilosis, Candida tropicalis, Chrysosporium sp., Cladosporium sp., Coccidioides immitis, Cryptococcus neoformans var gattii serotype B, Cryptococcus neoformans serotype A, Cryptococcus laurentii, Cryptococcus terreus, Curvularia sp., Fusarium sp.

Abstract: Nucleic acid probes and primers are described for detecting fungi that cause disease in humans and animals, as well as spoilage of food and beverages. These probes can detect rRNA, rDNA or polymerase chain reaction products from a majority of fungi in clinical, environmental or food samples. Nucleic acid hybridization assay probes specific for Acremonium sp., Aspergillus clavatus, Aspergillus flavus, Aspergillus fumigatus, Aspergillus glaucus, Aspergillus nidulans, Aspergillus niger, Aspergillus ochraceus, Aspergillus terreus, Aspergillus unguis, Aspergillus ustus, Beauveria sp., Bipolaris sp., Blastoschizomyces sp., Blastomyces dermatitidis, Candida albicans, Candida glabrata, Candida guilliermondii, Candida kefyr, Candida krusei, Candida lusitaniae, Candida parapsilosis, Candida tropicalis, Chrysosporium sp., Cladosporium sp., Coccidioides immitis, Cryptococcus neoformans var gattii serotype B, Cryptococcus neoformans serotype A, Cryptococcus laurentii, Cryptococcus terreus, Curvularia sp., Fusarium sp.

Abstract: Nucleic acid probes and primers are described for detecting fungi that cause disease in humans and animals, as well as spoilage of food and beverages. These probes can detect rRNA, rDNA or polymerase chain reaction products from a majority of fungi in clinical, environmental or food samples. Nucleic acid hybridization assay probes specific for Aspergillus fumigatus, Blastomyces dermatitidis, Candida albicans, Coccidioides immitis, Cryptococcus neoformans, Histoplasma capsulatum, Aspergillus flavus, Aspergillus glaucus, Aspergillus niger, Aspergillus terreus, Candida glabrata, Candida guilliermondii, Candida kefyr, Candida krusei, Candida lusitaniae, Candida parapsilosis, Candida tropicalis, Pseudallescheria boydii, and Sporothrix schenckii are also described.

Abstract: The detection of the IS6110 insertion element in a clinical specimen is a rapid way of diagnosing infection by Mycobacterium tuberculosis. A reliable diagnostic test for tuberculosis based on the IS6110 DNA is described in this disclosure. A "Universal" specimen preparation protocol that eliminates live organisms and purifies nucleic acids from all types of clinical specimens is described. Two nucleic acid primers designed to amplify IS6110 DNA with high specificity in a polymerase chain reaction are also described. The amplified IS6110 DNA is identified by a restriction endonuclease and electrophoresis based assay. The identification process also renders the DNA unamplifiable in a subsequent PCR, thereby reducing the possibility of contaminating other specimens. Time, labor and cost is minimized, while user safety and test reliability are maximized.

Abstract: Nucleic acid probes and primers are described for detecting fungi that cause disease in humans and animals, as well as spoilage of food and beverages. These probes can detect rRNA, rDNA or polymerase chain reaction products from a majority of fungi in clinical, environmental or food samples. Nucleic acid hybridization assay probes specific for Acremonium sp., Aspergillus clavatus, Aspergillus flavus, Aspergillus fumigatus, Aspergillus glaucus, Aspergillus nidulans, Aspergillus niger, Aspergillus ochraceus, Aspergillus terreus, Aspergillus unguis, Aspergillus ustus, Beauveria sp., Bipolaris sp., Blastoschizomyces sp., Blastomyces dermatitidis, Candida albicans, Candida glabrata, Candida guilliermondii, Candida kefyr, Candida krusei, Candida lusitaniae, Candida parapsilosis, Candida tropicalis, Chrysosporium sp., Cladosporium sp., Coccidioides immitis, Cryptococcus neoformans var gattii serotype B, Cryptococcus neoformans serotype A, Cryptococcus laurentii, Cryptococcus terreus, Curvularia sp., Fusarium sp.